Paul Hastings Adds Capital Markets Partner in Hong Kong

Paul Hastings, a leading global law firm, announced today that Chaobo Fan has joined the firm’s Capital Markets practice as a partner in Hong Kong



“We’re meeting our clients’ demand for help with increasingly complex, multi-jurisdictional transactions,” said Seth Zachary, chair of Paul Hastings. “The arrival of top talent like Chaobo adds further depth to our Capital Markets practice in Hong Kong, one of the world’s premier listing markets.”



“Paul Hastings is a powerhouse in capital markets,” said Fan. “I look forward to working with talented colleagues to help clients pursue growth through innovative, complex transactions and manage their risks in today’s more complicated regulatory and geopolitical environment.”



Fan’s practice focuses on securities offerings, mergers and acquisitions, and other corporate matters. He previously practiced at Freshfields Bruckhaus Deringer and Latham & Watkins, and has extensive experience advising on prominent equity capital markets transactions. He is particularly experienced in advising Chinese companies on their listings on the Hong Kong Stock Exchange.



Fan’s arrival follows the recent addition of leading Capital Markets partner David Flechner in São Paulo and preeminent Leveraged Finance and Capital Markets partner Frank Lopez in New York. The addition of Fan further elevates the firm’s premier global Capital Markets practice, which represents sponsors, investment banks, and public and private companies in a broad range of equity and debt capital markets transactions, as well as public company advisory matters.



The global Capital Markets practice at Paul Hastings has advised on several landmark transactions in recent years, including US$5.5 billion of high yield notes issued in connection with Altice USA, Inc.’s combination of Suddenlink and Optimum; Minera Mexico’s US$1 billion senior notes offering; Unibail-Rodamco-Westfield US$750 million issuance of guaranteed senior notes; PagSeguro’s US$653 million follow-on offering; and Ascletis Pharma’s US$400 million IPO – the first listing under Chapter 18A of the listing rules in Hong Kong.

Leave a Reply